Nelarabine
As of the edition of 20 October 2026, Nelarabine is a small molecule: marketed, first approved in 2005 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2007
- Kind
- Small molecule
- Brand name
- Arranon
- First approved
- 28 October 2005 (US)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Sandoz
- Registered trials
- 29, 7 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Digestive system; Infections
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 5 | 0 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 17 | 6 | 3 | 7 |
| Phase 3 | 5 | 1 | 3 | 0 |
| All trials | 29 |